Mitotic rate and S-phase fraction as prognostic factors in stage I cutaneous malignant melanoma

British Journal of Cancer

Volumn 77, Issue 11, 1998, Pages 1917-1925

  Karjalainen, J M ^a,b   Eskelinen, M J ^a   Nordling, S ^c   Lipponen, P K ^b   Alhava, E M ^a   Kosma, V M ^a,b  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Breslow; Clark; Cutaneous malignant melanoma; DNA flow cytometry; Mitotic rate; Prognosis

Indexed keywords

DNA;

ADULT; AGED; ARTICLE; BLEEDING; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE S PHASE; CLINICAL FEATURE; FEMALE; GENDER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MELANOMA; MITOSIS RATE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

EID: 0031748832     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.318     Document Type: Article

References (47)

1. Baisch H, Göhde W and Linden WA (1975) Analysis of PCP-data to determine the fraction of cells in the various phases of cell cycle. Radiat Environ Biophys 12: 31-39
2. Barnhill RL, Fine JA, Roush GC and Berwick M (1996) Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer 78: 427-432
3. Bartkowiak D, Schumann J, Otto FJ, Lippold A and Drepper H (1991) DNA flow cytometry in the prognosis of primary malignant melanoma. Oncology 48: 39-43
4. Bergers E, van Diest PJ and Baak JPA (1996) Tumour heterogeneity of DNA cell cycle variables in breast cancer measured by flow cytometry. J Clin Pathol 49: 931-937
5. Breslow A (1970) Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 12: 902-908
6. Camplejohn R, MacCartney J and Morris R (1989) Measurement of S-Phase fractions in lymphoid tissue comparing fresh versus paraffin-embedded tissue and 4′,6′-diamidino-2-phenylindole dihydrochloride versus propidium iodide staining. Cytometry 10: 410-416
7. Clark WH Jr, From L, Bernardino EA and Mihm MC (1969) The histogenesis and biologic behaviour of primary human malignant melanomas of the skin. Cancer Res 29: 705-726
8. Clemente C, Mihm M, Bufalino R, Zurrida S, Collini P and Cascinelli N (1996) Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77: 1303-1310
9. Collan YUI, Kuopio T, Baak JPA, Becker R, Bogomoletz WV, Deverell M, van Diest P, van Galen C, Gilchrist K, Javed A, Kosma V-M, Kujari H, Luzi P, Mariuzzi GM, Matze E, Montironi R, Scarpelli M, Sierra D, Sisti S, Toikkanen S, Tosi P, Whimster WF and Wisse E (1996) Standardized mitotic counts in breast cancer; evaluation of the method. Pathol Res Pract 192: 931-941
10. Cox DR (1972) Regression models and life tables with discussion. J Stat Soc B 34: 187-192
11. Cross SS and Start RD (1996) Estimating mitotic activity in tumours. Histopathology 29: 485-488
12. Donhuijsen K (1986) Mitosis counts: reproducibility and significance in grading of malignancy. Hum Pathol 17: 1122-1125
13. Eastwood J and Baker TG (1984) Cutaneous malignant melanoma in West Yorkshire. II. A prospective study of recurrence and prediction of lymph nodal metastasis. Br J Cancer 50: 35-43
14. Eskelinen MJ, Lipponen PK, Papinaho S, Aaltomaa S, Kosma V-M, Klemi P and Syrjänen K (1992) DNA flow cytometry, nuclear morphometry, mitotic indices and steroid receptors as independent prognostic factors in female breast cancer. Int J Cancer 51: 555-561
15. Evans AT, Blessing K, Orrell JM and Grant A (1992) Mitotic indices, anti-PCNA immunostaining, and AgNORs in thick cutaneous melanomas displaying paradoxical behaviour. J Pathol 168: 15-22
16. Friedlander ML, Hedley DW and Taylor IW (1984) Clinical and biological significance of aneuploidy in human tumours. J Clin Pathol 37: 961-974
17. Garbe C, Buttner B, Bertz J, Burg G, d'Hoedt B, Drepper H, Guggenmoos-Holzmann I, Lechner W, Lippold A, Orfanos CE, Peters A, Rassner G, Stadler R and Stroebel W (1995) Primary cutaneous melanoma. Identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer 75: 2484-2491
18. Gattuso P, Reddy V, Solans E, Kathuria S, Aranha GV, Jacobs HK and Walloch J (1990) Is DNA ploidy of prognostic significance in stage I cutaneous melanoma? Surgery 108: 702-708; discussion 708-709
19. Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach C, Kloth S, Brandt E and Flad HD (1991) Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 138: 867-873
20. Haapasalo H, Pesonen E and Collan Y (1989a) Volume-corrected mitotic index (M/V-index). The standard of mitotic activity in neoplasms. Pathol Res Pract 185: 551-554
21. Haapasalo H, Collan Y, Atkin N and Seppä A (1989b) Prognosis of ovarian carcinomas: prediction by histoquantitative methods. Histopathology 15: 167-178
22. Hedley DW, Friedlander ML, Taylor IW, Rugg CA and Musgrove EA (1983) Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 31: 1333-1335
23. Jannink I, Risberg B, van Diest PJ and Baak JPA (1996) Heterogeneity of mitotic activity in breast cancer. Histopathology 29: 421-428
24. Jochum W, Schröder S, Al-Taha R, August C, Gross A, Berger J and Padberg B-C (1996) Prognostic significance of nuclear DNA content and proliferative activity in renal cell carcinomas. A clinicopathological study of 58 patients using mitotic count, MIB-1 staining and DNA cytophotometry. Cancer 77: 514-521
25. Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
26. Kallioniemi OP (1988) DNA flow cytometry in oncology - methodology and prognostic value in breast and ovarian cancer. Cytometry 9: 164-169
27. Keshgegian AA and Cnaan A (1995) Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1. Am J Clin Pathol 104: 42-49
28. Kheir SM, Bines SD, von Roenn JH, Soong S-J and Coon JS (1988) Prognostic significance of DNA aneuploidy in stage I cutaneous melanoma. Ann Surg 207: 455-461
29. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC and Blum RH (1996) Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the eastern cooperative oncology group trial EST 1684. J Clin Oncol 14: 7-17
30. Lindholm C, Hofer P, Jonsson H and Tribukait B (1989) Flow DNA-cytometric findings of paraffin embedded primary cutaneous melanomas related to prognosis. Virchows Arch B 58: 147-151
31. Lipponen PK, Kosma V-M, Collan Y, Kulju T, Kosunen O and Eskelinen MJ (1990) Potential of nuclear morphometry and volume corrected mitotic index in grading transitional-cell carcinoma of the urinary bladder. Eur J Urol 17: 333-337
32. Lipponen PK, Eskelinen MJ and Nordling S (1991) Intratumoral heterogeneity of DNA indexes in transitional cell bladder cancer: relation to tumour histology. Eur Urol 20: 311-314
33. Montironi R, Collan Y, Scarpelli M, Sisti S, Barbatelli G, Carnevali A, Pisani E and Mariuzzi GM (1988) Reproducibility of mitotic counts and identification of mitotic figures in malignant glial tumours. Appl Pathol 6: 258-265
34. Muhonen T, Pyrhönen S, Laasonen A, Wasenius V-M, Asko-Seljavaara S, Franssila K and Kangas L (1992) Tumour growth rate and DNA flow cytometry parameters as prognostic factors in metastatic melanoma. Br J Cancer 66: 528-532
35. Quinn CM and Wright NA (1990) The clinical assessment of proliferation and growth in human tumours: evaluation of methods and applications as prognostic variables. J Pathol 160: 93-102
36. Ramsay JA, From L, Iscoe NA and Kahn HJ (1995) MIB-1 proliferative activity is a significant prognostic factor in primary thick cutaneous melanomas. J Invest Dermatol 105: 22-26
37. Reddy VB, Gattuso P, Aranha G and Carson HJ (1995) Cell proliferation markers in predicting metastases in malignant melanoma. J Cutan Pathol 22: 248-251
38. Salman SM and Rogers GS (1990) Prognostic factors in thin cutaneous malignant melanoma. J Dermatol Surg Oncol 16: 413-418
39. Schmoeckel C and Braun-Falco O (1978) Prognostic index in malignant melanoma. Arch Dermatol 114: 871-873
40. Seckinger D, Sugarbaker E and Frankfurt O (1989) DNA content in human cancer. Arch Pathol Lab Med 113: 619-626
41. Straume O and Akslen LA (1996) Independent prognostic importance of vascular invasion in nodular melanomas. Cancer 78: 1211-1219
42. Takahashi H, Strutton GM and Parsons PG (1991) Determination of proliferating fractions in malignant melanomas by anti-PCNA/cyclin monoclonal antibody. Histopathology 18: 221-227
43. Talve L, Kainu J, Collan Y and Ekfors T (1996) Immunohistochemical expression of p53 protein, mitotic index and nuclear morphometry in primary malignant melanoma of the skin. Pathol Res Pract 192: 825-833
44. UICC (1987) TNM Classification of Malignant Tumours. Fourth, fully revised edition. Berlin, Springer-Verlag, pp. 88-90
45. Vogt T, Zipperer K-H, Vogt A, Hölzel D, Landthaler M and Stolz W (1997) p53 protein and Ki-67 antigen expression are both reliable biomarkers of prognosis in thick stage I nodular melanomas of the skin. Histopathology 30: 57-63
46. von Roenn JH, Kheir SM, Wolter JM and Coon JS (1986) Significance of DNA abnormalities in primary malignant melanoma and nevi: a retrospective flow cytometric study. Cancer Res 46: 3192-3195
47. Weidner N, Moore DH and Vartanian R (1994) Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel 'paraffin'-reactive MIB-I antibody. Hum Pathol 25: 337-342